Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human BRAF Antikörper:
anti-Rat (Rattus) BRAF Antikörper:
anti-Mouse (Murine) BRAF Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal BRAF Primary Antibody für FACS, WB - ABIN1881118
Hingorani, Jacobetz, Robertson, Herlyn, Tuveson: Suppression of BRAF(V599E) in human melanoma abrogates transformation. in Cancer research 2003
Show all 6 Pubmed References
Human Monoclonal BRAF Primary Antibody für IHC, ELISA - ABIN1724658
Rapp, Goldsborough, Mark, Bonner, Groffen, Reynolds, Stephenson: Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. in Proceedings of the National Academy of Sciences of the United States of America 1983
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody für IHC, ELISA - ABIN965693
Kim, Giuliano, Turner, Gaffney, Umetani, Kitago, Elashoff, Hoon: Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. in Annals of surgery 2006
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody für ICC, IHC - ABIN968991
Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008
Show all 2 Pubmed References
Human Monoclonal BRAF Primary Antibody für PLA, ELISA - ABIN513800
Liu, Chen, Chau, Jan, Chen, Hsu, Lin, Juang, Lu, Cheng, Chen, Chang, Ting, Kao, Hsiao, Huang: Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma. in Molecular & cellular proteomics : MCP 2013
Human Polyclonal BRAF Primary Antibody für ELISA, IHC (p) - ABIN5573331
Wiggans, Reilly, Kass, Maggs: Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma. in Veterinary ophthalmology 2016
Human Polyclonal BRAF Primary Antibody für DB - ABIN389897
Frattini, Ferrario, Bressan, Balestra, De Cecco, Mondellini, Bongarzone, Collini, Gariboldi, Pilotti, Pierotti, Greco: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. in Oncogene 2004
Show all 3 Pubmed References
the present study identifies the WIPF1 (zeige WIPF1 Antikörper) gene as having novel oncogenic functions and playing an important role in the invasiveness and aggressiveness of thyroid cancer when aberrantly up-regulated by the BRAF V600E/MAPK (zeige MAPK1 Antikörper) pathway through its promoter demethylation.
BRAF mutation is associated with colonic neuroendocrine carcinoma.
c-Myc (zeige MYC Antikörper), a downstream key effector of BRAF(V600E) signaling, was required for BRAF(V600E)-induced changes in lysine27-trimethylated histone H3 (zeige HIST3H3 Antikörper) through regulating the components of the polycomb (zeige CBX2 Antikörper) repressive complex 2 (PRC2) genes Ezh2 (zeige EZH2 Antikörper), Suz12 and Jarid2 (zeige JARID2 Antikörper) at both transcriptional levels via direct binding to their regulatory elements and post-transcriptional levels via repressing the miR (zeige MLXIP Antikörper)-26a, miR (zeige MLXIP Antikörper)-200b and miR (zeige MLXIP Antikörper)-155.
Data show that depletion of SRY (sex determining region Y)-box 10 (zeige SOX10 Antikörper) protein (SOX10 (zeige SOX10 Antikörper)) sensitizes mutant proto-oncogene (zeige RAB1A Antikörper) proteins B-raf (BRAF) melanoma cells to RAF (zeige RAF1 Antikörper) inhibitors in vitro and in vivo.
A panRAF inhibitor, LY3009120, potently inhibited proliferation and tumor growth in BRAF/KRAS mutated colorectal tumors.
In the coBRIM phase III trial, the addition of cobimetinib, an MEK (zeige MAP2K1 Antikörper) inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs (zeige AES Antikörper)) in the coBRIM study
Report heterogeneity and frequency of BRAF mutations in primary melanoma samples.
Using a panel of BRAF V600E and WT colorectal cancer cell lines and in vitro selected resistant culture, and xenograft models, authors demonstrate here that BRAFV600E confers resistance to mTOR (zeige FRAP1 Antikörper) inhibitors.
Our model is trained to mimic the predictions of a 64-gene signature, the current definition of BRAF-positive group.
pediatric papillary thyroid carcinomas in Japan are characterized by more advanced clinicopathological features, lower BRAF (V600E) frequency, and absence of TERT (zeige TERT Antikörper) mutation
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.
Gene expression studies nominated TWIST2 (zeige TWIST2 Antikörper) as a key effector downstream of BRAF.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.
BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.
BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.
mosaic expression of BRAF(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder
CDX2 (zeige CDX2 Antikörper)(Null)/BRAF(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF(V600E) potently interacted with CDX2 (zeige CDX2 Antikörper) silencing to alter gene expression. Like human serrated lesions, CDX2 (zeige CDX2 Antikörper)(Null)/BRAF(V600E)-mutant epithelium expressed gastric markers.
expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis
TTM (zeige SLITRK1 Antikörper) reduces copper levels and MAPK (zeige MAPK1 Antikörper) signaling, thereby inhibiting BRAF(V600E)-driven melanoma tumor growth.
BRAF and ROKalpha (zeige ROCK2 Antikörper) form independent RAF1 (zeige RAF1 Antikörper) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (zeige EGF Antikörper)).
Braf(V600E) expression, coupled with simultaneous p53 (zeige TP53 Antikörper) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF(V600E) in metastasis.
Mechanistically, BRAF and RAF1 (zeige RAF1 Antikörper) operate independently to balance MAPK (zeige MAPK1 Antikörper) signaling: BRAF promotes ERK (zeige EPHB2 Antikörper) activation, while RAF1 (zeige RAF1 Antikörper) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF interacts and phosphorylates PAX3 (zeige PAX3 Antikörper).
Using a conditional allele for Braf(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
94 kDa B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, murine sarcoma viral (v-raf) oncogene homolog B1
, proto-oncogene B-Raf
, serine/threonine-protein kinase B-raf
, v-raf murine sarcoma viral oncogene homolog B1
, B-Raf proto-oncogene serine/threonine-protein kinase
, proto-oncogene c-Rmil
, rmil serine/threonine-protein kinase
, serine/threonine kinase
, serine/threonine-protein kinase Rmil
, serine/threonine protein kinase BRAF
, serine/threonine-protein kinase B-raf-like
, B-raf protein